二代测序技术在消化系统肿瘤临床应用的中国专家共识

Chinese expert consensus on next generation sequencing for gastrointestinal cancers

消化系统肿瘤是发病率和致死率均较高的一类实体肿瘤。随着精准医疗在消化系统肿瘤领域的不断深入,以及相关分子标志物研究的不断积累,临床对于消化系统肿瘤的基因检测和应用提出了更高的要求。二代测序(next-generation sequencing,NGS)技术大大提高了检测通量,降低了单个样本单个位点的测序成本,在消化系统肿瘤中的应用越来越广泛。然而,NGS检测提供了大量的肿瘤基因组信息,如何在异常复杂的消化系统肿瘤中正确应用是巨大的挑战。为提高消化系统肿瘤中NGS技术临床应用的规范性,中国抗癌协会肿瘤精准治疗专业委员会结合国内外研究成果,形成了《二代测序技术在消化系统肿瘤临床应用的中国专家共识》。本共识旨在为NGS技术指导临床消化系统肿瘤精准诊疗提供理论基础与规范,并对消化系统肿瘤的临床诊疗提供有效帮助。

Gastrointestinal cancers are a group of solid tumors with high incidence and mortality rates.With the growing understanding of precision medicine and the continuous generation of clinical evidence,molecular marker testing is required for the diagnosis and treatment of gastrointestinal cancers.Next-generation sequencing(NGS)technology has significantly evolved to provide increased data output and efficiencies,and has been more and more widely used in gastrointestinal cancers.In order to improve the standardization of the clinical application of NGS technology in gastrointestinal cancers,an expert panel organized by the Society of Cancer Precision Medicine of the Chinese Anti-Cancer Association has formulated the Chinese expert consensus on next generation sequencing for gastrointestinal cancers based on current evidence and clinical studies.This expert consensus aims to provide guidance for Chinese clinicians on NGS technology in gastrointestinal cancers.